Candel Therapeutics CEO to Present at Two Key Investor Conferences
Event summary
- Candel Therapeutics CEO Paul Peter Tak to present at Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, and Jefferies Global Healthcare Conference on June 3, 2026.
- Company's lead product candidate, aglatimagene besadenovec, completed phase 2a trials in NSCLC and PDAC, with a phase 3 trial ongoing in localized prostate cancer.
- Linoserpaturev (CAN-3110) in phase 1b trial for recurrent high-grade glioma, with Fast Track and Orphan Drug Designations from FDA.
- Candel's enLIGHTEN™ Discovery Platform aims to develop new viral immunotherapies for solid tumors.
The big picture
Candel Therapeutics' participation in high-profile investor conferences underscores its strategic focus on advancing multimodal immunotherapies for cancer. The company's progress in clinical trials and regulatory designations positions it within the competitive landscape of oncology biotech, where innovation and speed to market are key differentiators. The upcoming presentations will provide insights into the company's pipeline and potential for securing additional investment or partnerships.
What we're watching
- Clinical Trial Momentum
- The pace at which Candel Therapeutics advances its clinical trials, particularly the phase 3 trial for aglatimagene in prostate cancer, will be critical for regulatory approval and market positioning.
- Regulatory Designations
- The impact of FDA's Fast Track and Orphan Drug Designations on accelerating the development and approval process for Candel's product candidates.
- Investor Sentiment
- How the upcoming investor presentations will influence market perception and potential funding or partnership opportunities for Candel Therapeutics.